# Patent Watch: Avecho Targets Oral Cannabinoid Delivery

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-patent-watch-avecho-targets-oral-cannabinoid-2026-10-09/
> **Published:** 2026-10-09T12:15:06-04:00 | **Last Modified / Clinically Audited:** 2026-10-09T12:15:06-04:00
> **Clinical Summary:** Avecho’s application describes an oral cannabinoid formulation combining tocopheryl phosphates with long-chain triglycerides or long-chain fatty acids. Can

---

PATENT WATCH
 US20260183317A1
 
 

# Patent Watch: Avecho Targets Oral Cannabinoid Delivery With Phosphorylated Tocopherols

 
 **Assignee:** AVECHO BIOTECHNOLOGY LIMITED
 **Inventors:** Paul GAVIN
 **Published:** 2026-07-02
 
 

 
 Invention Summary & Claims
 

Avecho’s application describes an oral cannabinoid formulation combining tocopheryl phosphates with long-chain triglycerides or long-chain fatty acids. Cannabinoids are the intended active pharmaceutical ingredients, while the accompanying compounds appear intended as formulation excipients supporting delivery rather than separate therapeutic agents. The title identifies the combination, but its precise composition, claim boundaries, and dosage forms cannot be established from the bibliographic disclosure alone.

 

 

## Clinical Perspective & Therapeutic Significance

 

Lipid-based formulations can influence cannabinoid solubilization and gastrointestinal absorption, potentially addressing low or variable oral exposure. Whether this particular combination improves bioavailability, reduces food effects, or provides more predictable symptom control requires formulation-specific human studies. Increased absorption could also increase adverse effects at an unchanged dose, making dose calibration and interaction assessment important.

 

## Intellectual Property & Market Landscape

 

Avecho Biotechnology Limited is the applicant seeking protection for a formulation-based approach to oral cannabinoid delivery. Relative to conventional cannabinoid oils and capsules, the proposed differentiation is the tocopheryl phosphate and long-chain lipid combination, not necessarily a new cannabinoid API. Commercial significance will depend on the eventual claim scope, demonstrated performance, manufacturing practicality, and applicable regulatory requirements.

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (US20260183317A1)](https://patents.google.com/patent/US20260183317A1/en).
 

 
 Editorial Commentary
 

This application merits attention as a delivery-platform development, not as evidence of a new proven cannabis treatment. Its patient value will depend on whether the formulation delivers reproducible exposure and meaningful clinical benefits without compromising safety.

 

 
 

### Frequently Asked Questions

 
 Could this formulation make oral cannabinoids work more reliably?
 That is a plausible goal of lipid-based delivery, but improved reliability has not been established by the bibliographic disclosure. Human pharmacokinetic studies would need to assess exposure variability, food effects, and dose consistency.

 Does this patent application mean the formulation has passed clinical trials?
 No. A published patent application concerns intellectual property claims and does not establish clinical efficacy, safety, regulatory approval, or completion of clinical trials.

 When could patients obtain a product using this formulation?
 No availability date can be established from the application information. Access would depend on product development, supporting evidence, and the regulatory pathway in the relevant jurisdiction.

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).